Edaravone and its clinical development for amyotrophic lateral sclerosis.

about

What can we learn from the edaravone development program for ALS?Self-nanomicellizing solid dispersion of edaravone: part I – oral bioavailability improvement.

P2860

Q50222481-3F4BE7BD-A112-48D6-B45E-364BDC755C05 Q55686117-2661C1A2-CB81-4198-B498-E5B93C415DB6

P2860

Edaravone and its clinical development for amyotrophic lateral sclerosis.

Item

http://www.wikidata.org/entity/Q47782687

description

2017 nî lūn-bûn

@nan

2017 թվականի հոկտեմբերին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Edaravone and its clinical development for amyotrophic lateral sclerosis.

@en

Edaravone and its clinical development for amyotrophic lateral sclerosis.

@nl

type

Item

label

Edaravone and its clinical development for amyotrophic lateral sclerosis.

@en

Edaravone and its clinical development for amyotrophic lateral sclerosis.

@nl

prefLabel

Edaravone and its clinical development for amyotrophic lateral sclerosis.

@en

Edaravone and its clinical development for amyotrophic lateral sclerosis.

@nl

P1476

Edaravone and its clinical development for amyotrophic lateral sclerosis.

@en

P2093

Joseph Palumbo

http://www.w3.org/2001/XMLSchema#string

Kazutoshi Watanabe

http://www.w3.org/2001/XMLSchema#string

Koji Takei

http://www.w3.org/2001/XMLSchema#string

Makoto Akimoto

http://www.w3.org/2001/XMLSchema#string

Satoshi Yuki

http://www.w3.org/2001/XMLSchema#string

Takeshi Sakata

http://www.w3.org/2001/XMLSchema#string

P2860

A comprehensive review of amyotrophic lateral sclerosis

Redox regulation in amyotrophic lateral sclerosis

Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis

Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia.

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

Oxidative stress biomarkers in sporadic ALS

Lack of association between nuclear factor erythroid-derived 2-like 2 promoter gene polymorphisms and oxidative stress biomarkers in amyotrophic lateral sclerosis patients.

Oxidative stress interferes with white matter renewal after prolonged cerebral hypoperfusion in mice.

P304

5-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21678421.2017.1353101

http://www.w3.org/2001/XMLSchema#string

P433

sup1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28872907

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis

edaravone

Edaravone and its clinical development for amyotrophic lateral sclerosis.

about

P2860

P2860

Edaravone and its clinical development for amyotrophic lateral sclerosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921